The forecast for sold production of antisera, other immunological products, and other blood fractions in the UK indicates a decline in value from 357.06 million Euros in 2024 to 295.82 million Euros in 2028. This demonstrates a yearly decrease of approximately 4-5%. Unfortunately, the 2023 actual value is not provided, which limits an assessment of the initial variation. Over the five-year period, the compound annual growth rate (CAGR) suggests a consistent downward trend in market value.
Future trends to watch for include technological advancements in biologics and immunological R&D, potential regulatory changes, and fluctuations in global demand for immunological products, which could impact market dynamics and reverse or exacerbate current trends.
